Sort
82,697 grants matching “vaccine development”
HPV, HIV and Oral Microbiota Interplay in Nigerian Youth (HOMINY)
$953,985Modupe Coker · University Of Pennsylvania · R01 · FY2025 · DE
Disease Modeling of Influenza and Other Emerging Respiratory Viral Pathogens
$953,984Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
CAP: Trivalent Filovirus Vaccine for Pre- and Post-Exposure Vaccination
$953,984Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Molecular Pathogenesis of Neoplasia
$953,971John Heiss · National Institute Of Neurological Disorders And Stroke · ZIA · FY2023 · NS
Discovery of new cellular targets for small-molecule inhibition of enveloped vir
$953,766Sean P. J. Whelan · Harvard Medical School · U19 · FY2018 · AI
Combining membrane Env vaccine regimens to elicit multiple bnAb lineages and consistent cross-neutralization of HIV
$953,504Michael B Zwick · Scripps Research Institute, The · R01 · FY2024 · AI
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination
$953,477Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2024 · AI
RP3: Therapeutics Human Monoclonal Antibody Treatments for Filoviruses
$953,424James E Crowe · University Of Texas Med Br Galveston · U19 · FY2017 · AI
Core 1: Facility Management, Maintenance and Operations Core
$953,343Colin S. Duckett · Duke University · UC7 · FY2024 · AI
Immune Memory
$953,324Rafi Ahmed · Emory University · U19 · FY2014 · AI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV
$953,316Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Antibody-based Protection against Flavivirses
$953,281Michael S. Diamond · Washington University · R01 · FY2021 · AI
Molecular approaches to understand vector-host and vector-pathogen interactions
$953,262Jesus Valenzuela · Niaid Extramural Activities · Z01 · FY2007 · AI
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: NHP Purchase and Holding
$953,175Maria Grazia Ferrari · Advanced Bioscience Laboratories, Inc. · N01 · FY2021 · AI
Enhanced Oral Vaccine Delivery Vehicle
$953,135Sean N Tucker · Vaxart, Inc. · R44 · FY2009 · AI
Preventing HIV Infection in Women: Targeting Antiretrovirals to Mucosal Tissues
$953,109Angela D Kashuba · Univ Of North Carolina Chapel Hill · U01 · FY2012 · AI
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
$952,967Gary Fanger · Rise Therapeutics, Llc · R44 · FY2025 · AG
Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants
$952,926Timothy R Fouts · Profectus Biosciences, Inc. · R44 · FY2012 · AI
Development of Novel Therapeutic Agents for Norovirus Infection
$952,801Kyeong-Ok Chang · Kansas State University · U01 · FY2012 · AI
Pulsed EPR Spectrometer
$952,390Timothy A Springer · Immune Disease Institute, Inc. · S10 · FY2008 · RR
VACCINE AND TREATMENT EVALUATION UNITS (VTEU): PROTOCOL DEVELOPMENT AND IMPLEMENTATION, FOR A PHASE 1 ANTHRAX VACCINE TRIAL
$952,381Karen Kotloff · University Of Maryland Baltimore · N01 · FY2020 · AI
IHV/UM AITRP IN THE CARIBBEAN, BRAZIL AND NIGERIA
$952,320University Of Maryland Baltimore · D43 · FY2003 · TW
Vector Biological Studies in Leishmaniasis
$952,315David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Microneedle Delivery of Zanamivir for Treatment of Influenza
$952,176Elke Lipka · Tsrl, Inc. · R44 · FY2021 · AI
Interaction of HIV envelope with cell surface receptors
$952,044Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI